FDA to Review Re-Submitted Bristol-Myers Hepatitis C Drug

Thursday, March 12, 2015

Source: Reuters

Bristol-Myers Squibb Co said U.S. regulators have accepted the company's re-submitted marketing application for an experimental treatment for hepatitis C, following the drugmaker's decision last year to pull back its initial marketing request.

Bristol-Myers on Thursday said the U.S. Food and Drug Administration will review daclatasvir, its so-called NS5A inhibitor, for use in combination with Gilead Sciences Inc's potent and widely used Sovaldi treatment. It said the FDA is expected to make its decision within six months.

View All News »